According to DRG epidemiology, more than 35 million people in the United States suffer from migraines. Despite being underutilized, migraine prophylaxis is a core treatment approach in reducing migraine frequency, severity, and duration. Prescription options include a diverse mix of on- and off-label oral drugs, newly launched anti-CGRP MAbs (i.e., Amgen / Novartis’s Aimovig, Teva’s Ajovy, and Eli Lilly’s Emgality), and Allergan’s Botox, which the FDA approved specifically for chronic migraine prevention. Prophylaxis is both individualized and dynamic, as physicians adjust regimens to improve outcomes and/or avoid side effects. Understanding this patient journey provides needed context for new and existing players as new preventives establish themselves in the market.
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: Aimovig, Ajovy, Emgality, Botox, topiramate IR, Trokendi XR, Qudexy XR, topiramate XR, propranolol, amitriptyline, verapamil, others
Key analysis provided:
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.